The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.

Let’s discuss how Tardive Dyskinesia (TD) affects your life and what you can do to overcome these difficulties.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational ...

Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that ...

Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...

GOTHENBURG, SWEDEN / ACCESS Newswire / February 27, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 27, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a compa ...

Assemblyman Jeff Gonzalez (R-Indio) announced Monday the introduction of AB 641, which would create a public awareness ...

After suffering from a long battle with Tardive Dyskinesia and Parkinsons Disease Glenn R. Buddy Clark, age 69, passed away at the South Mountain Restoration Center on Sunday, February 16 ...

According to reports, Verma cited uninspiring guidance for the company's leading drug, Ingrezza (a treatment for movement disorder tardive dyskinesia). Management proffered guidance for Ingrezza ...

Additionally, it has been used for depression, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, autism, and tardive dyskinesia. Currently, the effects of DMAE aren't ...

Eight years after introducing the first treatment for tardive dyskinesia, we're on track to once again achieve double-digit year-over-year growth this year. While our guidance reflects a moderated ...

We report on a patient with tardive dyskinesia (TDK) treated with aripiprazole, a third-generation antipsychotic with partial D2 agonist-antagonist activity at both the dopamine and serotonin ...